Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DYN 
Dyne Therapeutics Inc (DYN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: DYN (3-star) is a STRONG-BUY. BUY since 20 days. Simulated Profits (42.37%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $35.41
1 Year Target Price $35.41
| 7 | Strong Buy |
| 6 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 201.41% | Avg. Invested days 45 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.62B USD | Price to earnings Ratio - | 1Y Target Price 35.41 |
Price to earnings Ratio - | 1Y Target Price 35.41 | ||
Volume (30-day avg) 14 | Beta 1.3 | 52 Weeks Range 6.36 - 35.68 | Updated Date 11/7/2025 |
52 Weeks Range 6.36 - 35.68 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.62 |
Earnings Date
Report Date 2025-11-04 | When - | Estimate -0.8398 | Actual -0.76 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.32% | Return on Equity (TTM) -60.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1222561937 | Price to Sales(TTM) - |
Enterprise Value 1222561937 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.87 | Shares Outstanding 142824687 | Shares Floating 123106311 |
Shares Outstanding 142824687 | Shares Floating 123106311 | ||
Percent Insiders 0.5 | Percent Institutions 95.23 |
Upturn AI SWOT
Dyne Therapeutics Inc
Company Overview
History and Background
Dyne Therapeutics, Inc. was founded in 2017. The company focuses on developing therapies for serious muscle diseases using its proprietary FORCE platform.
Core Business Areas
- Muscle Disease Therapeutics: Dyne develops targeted therapeutics for various muscle diseases, including myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD).
Leadership and Structure
Dyne is led by CEO John Crowley. The company has a board of directors and a management team focused on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- DMT-101 (DM1 Program): DMT-101 is Dyne's lead program, targeting myotonic dystrophy type 1 (DM1). It is currently in clinical trials. Market share data is not yet available as it is pre-commercialization. Competitors are focused on symptom management and gene therapy approaches such as those from Avidity Biosciences (RNA targeting therapies).
- Duchenne Muscular Dystrophy (DMD) Programs: Dyne is developing multiple programs for DMD, including compounds targeting specific exons. Market share is not yet applicable. Competitors include Sarepta Therapeutics (exon skipping) and Solid Biosciences (gene therapy).
- FSHD Program: Dyne also has a program targeting facioscapulohumeral muscular dystrophy (FSHD). Market share not available, as it is in early stages of development. Competitors are focusing on gene editing such as Fulcrum Therapeutics.
Market Dynamics
Industry Overview
The industry focuses on developing therapies for rare genetic diseases, especially muscle disorders. There's growing interest in targeted therapies and gene editing technologies.
Positioning
Dyne Therapeutics is positioned as a leader in targeted oligonucleotide therapies for muscle diseases. Its FORCE platform offers a competitive advantage in drug delivery and specificity.
Total Addressable Market (TAM)
The total addressable market for muscle disease therapies is estimated to be in the billions of dollars, considering the high unmet need and the high cost of rare disease treatments. Dyne is positioned to capture a significant portion of this market with successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary FORCE platform
- Strong intellectual property
- Experienced management team
- Promising preclinical and clinical data
Weaknesses
- Dependence on successful clinical trial outcomes
- High cash burn rate
- Limited commercial infrastructure
- Risk of regulatory setbacks
Opportunities
- Expansion to other muscle diseases
- Partnerships with larger pharmaceutical companies
- Accelerated regulatory pathways for rare diseases
- Positive clinical trial results driving market adoption
Threats
- Competition from other gene therapy and oligonucleotide companies
- Clinical trial failures
- Regulatory hurdles
- Pricing pressures
Competitors and Market Share
Key Competitors
- SRPT
- AVDL
- PTCT
Competitive Landscape
Dyne's advantages lie in its FORCE platform and targeted approach. Disadvantages stem from its early stage of development compared to more established competitors. The above market share data is an estimate for the overall muscle disease therapeutics market.
Growth Trajectory and Initiatives
Historical Growth: Dyne's historical growth has been driven by preclinical and clinical advancements.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst projections are highly variable based on clinical trial readouts.
Recent Initiatives: Dyne's recent initiatives include advancing its clinical programs for DM1 and DMD, as well as expanding its research pipeline.
Summary
Dyne Therapeutics is a promising biotechnology company focused on developing therapies for muscle diseases. Its FORCE platform offers a potential advantage. However, the company faces risks associated with clinical trial outcomes and competition. The company has a high cash burn rate so it needs to secure future sources of funding.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Dyne Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates based on available information and may not be precise. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dyne Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2020-09-17 | CEO, President & Director Mr. John G. Cox M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 206 | Website https://www.dyne-tx.com |
Full time employees 206 | Website https://www.dyne-tx.com | ||
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.